Director, Gene and Cell Therapy/Immunotherapy
Sarcoma Oncology Research Center
Dr. Gordon is a practicing medical oncologist and serves as Director of Gene and Cell Therapy/Immunotherapy and Chairman of the Institutional Biosafety Committee at the Cancer Center of Southern California/Sarcoma Oncology Research Center, an academic medical institution that conducts ~15 active pharma-sponsored and investigator initiated/sponsored clinical trials for cancer. Dr. Gordon is also Founder of three biotechnology companies and President of the Aveni Foundation, a 501c3 public charity, whose mission is to expedite the development of gene targeted technologies for cancer, Parkinson's and other unmet medical needs. Dr. Gordon is internationally known in the field of gene therapy, specifically, for the invention and clinical development of DeltaRex-G, the first and, so far, only, tumor/disease-targeted genetic medicine that has gained Accelerated Approval for chemotherapy resistant solid malignancies in the Philippines in 2007, orphan drug designation for pancreatic cancer, soft tissue sarcoma and osteosarcoma in 2008, and Fast Track Designation for pancreatic cancer in the United States in 2009. Currently, Dr. Gordon serves as Sponsor/Principal Investigator of Blessed: An Expanded Access Program Using DeltaRex-G for Advanced Pancreatic Cancer, Sarcoma.and Breast Cancer. In this program, the USFDA has authorized the use of DeltaRex-G as platform therapy upon which one or more FDA approved cancer drugs/immunotherapies may be added.
Dr. Gordon licensed the first academic Viral Vector Production Facility in the world in 1994, has an extensive ntellectual property portfolio, and has published over 100 peer-reviewed articles. She was recipient of a Research Career Development Award from the United States NIH, multiple awards from the United States Local and National American Heart Association, RO1 research award from the USFDA, an Award for Excellence in Biotechnology from the City of Los Angeles, CA and the Thomas Award for Medical Research from the UST Medical Alumni Association in 2016 and 2021.
